Back To Search Results

Dr Ang Soo Fan

MBBS

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Upper Gastrointestinal

Conditions Treated by this Doctor:
Oesophagus Cancer , Stomach Cancer .

Clinical Appointments

Senior Consultant Division of Medical Oncology National Cancer Centre Singapore

Academic Appointments

Clinical Lecturer

Profile

Dr Ang Soo Fan holds dual appointments in National Cancer Centre Singapore and Penang Adventist Hospital since 2012. He is also a clinical lecturer at Yong Loo Lin School of Medicine Singapore. He was awarded with Bachelor of Medicine and Surgery (MBBS) in University of Malaya, Malaysia in 2001, membership of Royal College of Physicians of Edinburgh, United Kingdom in 2007 and obtained specialist accreditation for Medical Oncology, Academy of Medicine, Singapore in 2011.

He sub –specializes in gastrointestinal cancers and has a research interest in liver cancer and personalized treatments. He has been an invited speaker in both local and international seminars and conferences on his research. For example, he spoke about Choosing the Best First Line Combination Therapy for Metastatic Colorectal Cancer at the Colorectal Cancer Symposium earlier this year in Sri Lanka. He also talked about Management of borderline resectable liver only metastases in CRC during the Roche Oncology Scientific Meeting (ROSM) in March 2015.

Education

M.B.B.S (2001)

Professional Appointments and Committee Memberships

Professional Appointment

2012 - Current Consultant, Penang Adventist Hospital Consul
2012 - Current Department of Medical Oncology, National Cancer Centre

Committee Memberships

2011 Fellow of Academy of Medicine Singapore (FAMS)
2010 Fellow of American Society of Clinical Oncology (ASCO)
2008 Member of Singapore Society of Oncology (SSO)
2007 Member of Royal Colleges of Physicians of Edinburgh (UK)

Awards

2011/12 Singapore Health Quality Service Award
2006 Klang General Hospital Excellence Service Award

Research Interests

Publications

The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. PLoS One. 2015 Apr 1
Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients. Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, Madhukumar P, Ooi WS, Chay WY, Dent RA, Ang SF, Lo SK, Yap YS, Ng R, Chan A. J Clin Epidemiol. 2014; Epub 2014 Mar 18.
Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kan R, Lim WT, Tan SH, Ong WS, Cheung YB, Tan EH, Connolly JE, Gottschalk S, Toh HC. Mol Ther. 2014 Jan;22(1):132-9
Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. Soo-Fan Ang, Wang WW, Kumar R, Heah C, Utama A, Tania NP, Li H, Tan SH, Poo D, Choo SP, Chow WC, Tan CK, Toh HC. PLoS One. 2013 Jul 18
Effects of Chemotherapy and Psychosocial Distress on Perceived Cognitive Disturbances in Asian Breast Cancer Patients. Yin Ting Cheung, Maung Shwe, Wai Keung Chui, Wen Yee Chay, Soo-Fan Ang, Rebecca Alexandra Dent, Yoon Sim Yap, Soo Kien Lo, Raymond Chee Hui Ng, and Alexandre Chan. The Annals of Pharmacotherapy. Ann Pharmacother. 2012 Dec; 46(12):1645-55.
Activity of Thalidomide and Capecitabine in Advanced Hepatocellular Carcinoma with poorer liver function. Soo-Fan Ang, Sze-Huey Tan, Han-Chong Toh, Donald YH Poon, Simon YK Ong, Kian-Fong Foo, Su-Pin Choo. Am J Clin Oncol. 2012 Jun; 35(3):222-7
Infectious Causes of Cancer. 2010. Salubris, NCCS’s public Newsletter, Singapore
Latest Treatment Options for Liver Cancer. 2009. Medical Grapevine, Singapore
EBV-specific T cells in combination with chemotherapy show promising activity in the front-line treatment of patients with advanced nasopharyngeal carcinoma. Submitted to Science Translational Medicine on 18.7.2013
Protein expression of cancer-testis antigens in hepatocellular carcinoma from Singapore and correlation with clinical characteristics and outcomes. Soo-Fan Ang, Geoffrey Y. Ku, Han-chong Toh, Sze-Huey Tan, Giulio Spagnoli, Denise Frosina, Nicole Hanson, Jodie Tassello and Achim A. Jungbluth. Cancer Immunity 2012

Research Trials

Primary Investigator: Starts 2012: A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients (JPEC Reference No: 11-13-0398)
Co-I: Starts Jan 2012: Phase III Multi-Centre Open-Label Randomised Controlled Trial of Selective Internal Radiation Therapy (SIRT) Vesus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
Co-I: Starts Dec 08 ASCOT: Aspirin for Dukes C And High Risk Dukes B Colon Cancer – An International Multi-Centre, Double Blind, Randomized Placebo Controlled Phase III Trial (07-32-LGI)
Co-I: A Phase 1/2 Study of AZD6244 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma
Co-I: Pyridoxine study for patients starting on capecitabine as single-agent chemo.
Co-I: Identification of potential biomarkers in early resectable hepatocellcular carcinoma
Co-I: Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Compared to Weekly Paclitaxel Alone Followed in Both Arms by Doxorubicin and Cyclophosphamide for Operable or Locally Advanced Basal-like Subtype Breast Cancer Correlating BRCA-1 mRNA and Protein Expression with Carboplatin Response